Back to search

Article

Add-on Iguratimod or Tacrolimus in Methotrexate Inadequate Rheumatoid Arthritis: Efficacy, Safety and Propensity Score-Matched Analysis

2025-11-23

Abstract excerpt

<title>Abstract</title> <p> Background To evaluate the efficacy and safety of combination therapy with iguratimod (IGU) versus tacrolimus (TAC) plus methotrexate (MTX) in patients with rheumatoid arthritis (RA) who failed to achieve remission with MTX monotherapy. Methods This retrospective, single-centre study included RA patients treated with IGU + MTX (n = 56) and TAC + MTX (n = 52). Propensity score matching...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f132a43e-3366-58d6-ab27-9cb40f8824b8
DOI
10.21203/rs.3.rs-8026013/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Add-on Iguratimod or Tacrolimus in Methotrexate Inadequate Rheumatoid Arthritis: Efficacy, Safety and Propensity Score-Matched AnalysisDOI 10.21203/rs.3.rs-8026013/v1
Effectiveness and Safety of Intravenous Golimumab With and Without Concomitant Methotrexate in Patients With Rheumatoid Arthritis in the Prospective, Noninterventional AWARE StudySemantic proximity
Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registrySemantic proximity
Differences and Similarities in Clinical and Functional Responses Among Patients Receiving Tofacitinib Monotherapy, Tofacitinib Plus Methotrexate, and Adalimumab Plus Methotrexate: A Post-hoc Analysis of Data From Oral StrategySemantic proximity
Patient-Reported Outcomes of Upadacitinib Versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 TrialSemantic proximity
Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.Semantic proximity
Safety of JAK and IL-6 inhibitors in rheumatoid arthritis: a multicentor cohort studySemantic proximity
Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registriesSemantic proximity
Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss Clinical Quality Management cohortSemantic proximity
Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.Semantic proximity
Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritisSemantic proximity
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.Semantic proximity
Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infectionSemantic proximity
Select a neighboring publication to make it the new centre.